secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001193125-24-218131
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics raises ~$258.8M in public offering of common and Series B preferred stock
--------------------------------------------------------------------------------

- 10,666,600 common shares at $18.75/share and 20,000 Series B non-voting convertible preferred shares at $1,250.06250/share offered.
- Underwriters' option for 1,800,000 additional common shares exercised in full on September 12, 2024.
- Aggregate gross proceeds approximately $258.8 million before underwriting discounts and expenses.
- Net proceeds expected to fund operations into the second half of 2027.
- Closing of the offering expected on September 13, 2024 under existing shelf registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524218131/0001193125-24-218131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524218131/d881013d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-218131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer